Citius Pharmaceuticals (CTXR) vs Passage Bio (PASG)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Passage Bio (PASG) has outperformed Citius Pharmaceuticals (CTXR) over the past year, losing 54.3% versus a loss of 62.0%. Over five years, PASG leads with a -98.1% price change compared with -99.1% for CTXR. Citius Pharmaceuticals is the larger company by market cap ($13.4 million vs $12.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CTXR | PASG |
|---|---|---|
| Share price | $0.4887 | $3.78 |
| Market cap | $13.42M | $12.16M |
| 1-day change | -2.47% | -1.95% |
| YTD return | -37.10% | -67.97% |
| 1-year return | -61.97% | -54.35% |
| 5-year return | -99.06% | -98.06% |
| EPS (TTM) | $-1.75 | $-11.33 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.19 | $20.00 |
| 52-week low | $0.469 | $3.29 |
| Distance from 52-week high | -77.68% | -81.10% |
| Analyst consensus | none | buy |
| Avg. price target upside | +718.50% | +310.05% |
| Average volume | 527.79K | 26.11K |
| Shares outstanding | 27.45M | 3.22M |
| Employees | 23 | 24 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Citius Pharmaceuticals
CTXR stock →Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 23 employees
About Passage Bio
PASG stock →Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 24 employees
CTXR vs PASG FAQ
Which is bigger, Citius Pharmaceuticals or Passage Bio?
Citius Pharmaceuticals (CTXR) is larger, with a market capitalization of $13.42M compared with $12.16M for Passage Bio (PASG).
Which stock has performed better over the past year, CTXR or PASG?
PASG returned -54.35% over the past 12 months, compared with -61.97% for CTXR (price return, excluding dividends). Past performance does not predict future results.
Are Citius Pharmaceuticals and Passage Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Citius Pharmaceuticals and Biotechnology: Biological Products (No Diagnostic Substances) for Passage Bio.